Associated Papers
Assessing endocrine resistance: monitoring circulating ESR1 mutations in Irosustat-treated ER positive breast cancer.
Page K et al.
Breast Cancer Research and Treatment, 2025
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer.
Yarunin A et al.
Expert Review of Molecular Diagnostics, 2025
Evolutionary Overview and Future Perspectives: ESR1 Mutations, Liquid Biopsy, and Artificial Intelligence for a New Era of Personalized Medicine in ER+ Breast Cancer.
Martella S et al.
Molecular Diagnosis & Therapy, 2025
Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review.
Abujamous L et al.
The Oncologist, 2025
Screening and identification of HLA-A2-restricted neoepitopes for immunotherapy in endocrine therapy-resistant breast cancer.
Wang M et al.
Neoplasia (new York, N.y.), 2025
Molecular Profiling of Endocrine Resistance in HR+/HER2-Metastatic Breast Cancer: Insights from Extracellular Vesicles-Derived DNA and ctDNA in Liquid Biopsies.
Martínez-Rodríguez A et al.
International Journal of Molecular Sciences, 2024
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H et al.
Oncogene, 2024
EstroGene2.0: A multi-omic database of response to estrogens, ER-modulators, and resistance to endocrine therapies in breast cancer.
Li Z et al.
Biorxiv : the Preprint Server for Biology, 2024
Estrogen receptor α K303R mutation reorganizes its binding to forkhead box protein A1 regions and induces chromatin opening.
Nakadai T et al.
Molecular Biology Reports, 2023
Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR.
Ahn SG et al.
Npj Breast Cancer, 2022
Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling.
Wu LR et al.
Nature Communications, 2022
Highly sensitive liquid biopsy Duplex sequencing complements tissue biopsy to enhance detection of clinically relevant genetic variants.
Hallermayr A et al.
Frontiers in Oncology, 2022
DeteX: A highly accurate software for detecting SNV and InDel in single and paired NGS data in cancer research.
Cui Y et al.
Frontiers in Genetics, 2022
Calibration-free NGS quantitation of mutations below 0.01% VAF.
Dai P et al.
Nature Communications, 2021
Estrogen receptor-α signaling in post-natal mammary development and breast cancers.
Rusidzé M et al.
Cellular and Molecular Life Sciences : Cmls, 2021
Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability.
Jeffreys SA et al.
Cells, 2020
Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer.
Zhu W et al.
Oncotargets and Therapy, 2020
Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel.
Froyen G et al.
Cancers, 2019
The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy.
De Santo I et al.
Cancers, 2019
Estrogen receptor 1 mutations in 260 cervical cancer samples from Chinese patients.
Yang XM et al.
Oncology Letters, 2019
Insights into how phosphorylation of estrogen receptor at serine 305 modulates tamoxifen activity in breast cancer.
Kastrati I et al.
Molecular and Cellular Endocrinology, 2019
Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG et al.
Breast Cancer Research : Bcr, 2019
Personalized medicine in breast cancer: pharmacogenomics approaches.
Jeibouei S et al.
Pharmacogenomics and Personalized Medicine, 2019
Dynamics Insights Into the Gain of Flexibility by Helix-12 in ESR1 as a Mechanism of Resistance to Drugs in Breast Cancer Cell Lines.
Khan A et al.
Frontiers in Molecular Biosciences, 2019
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.
Pejerrey SM et al.
Hormones & Cancer, 2018
Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole.
Gyanchandani R et al.
Oncotarget, 2017
Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.
Yanagawa T et al.
Breast Cancer Research and Treatment, 2017
ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.
Angus L et al.
Cancer Treatment Reviews, 2017
ESR1 Mutations in Cell-Free DNA of Breast Cancer: Predictive "Tip of the Iceberg".
Fuqua SA et al.
Jama Oncology, 2016
Selective binding of estrogen receptor α to ubiquitin chains.
Pesiri V et al.
Iubmb Life, 2016
ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
Gelsomino L et al.
Breast Cancer Research and Treatment, 2016
Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.
Wang P et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Functional annotation of rare gene aberration drivers of pancreatic cancer.
Tsang YH et al.
Nature Communications, 2016
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.
Jeselsohn R et al.
Nature Reviews. Clinical Oncology, 2015
Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.
Jordan VC et al.
Journal of the National Cancer Institute, 2015
Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight.
Fuqua SA et al.
Breast Cancer Research and Treatment, 2014
D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.
Merenbakh-Lamin K et al.
Cancer Research, 2013
Association of estrogen receptor-α A908G (K303R) mutation with breast cancer risk.
Abbasi S et al.
International Journal of Clinical and Experimental Medicine, 2013
Mutations and polymorphisms of estrogens receptors genes and diseases susceptibility.
Kallel I et al.
Journal of Receptor and Signal Transduction Research, 2012
Structural basis for Ca2+-induced activation and dimerization of estrogen receptor α by calmodulin.
Zhang Y et al.
The Journal of Biological Chemistry, 2012
Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells.
Barone I et al.
Cancer Research, 2012
A conserved surface on the ligand binding domain of nuclear receptors for allosteric control.
Buzón V et al.
Molecular and Cellular Endocrinology, 2012
Estrogen receptor genes variations and breast cancer risk in Iran.
Abbasi S et al.
International Journal of Clinical and Experimental Medicine, 2012
Absence of the K303R estrogen receptor α mutation in breast cancer patients exhibiting different responses to aromatase inhibitor anastrozole neoadjuvant treatment.
Ghimenti C et al.
Experimental and Therapeutic Medicine, 2010